Comparative Pharmacology
Head-to-head clinical analysis: MAYZENT versus TASCENSO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAYZENT versus TASCENSO ODT.
MAYZENT vs TASCENSO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It binds to S1P receptors on lymphocytes, inducing internalization and degradation of the receptor, thereby preventing egress of lymphocytes from lymph nodes, reducing peripheral lymphocyte count and immune-mediated demyelination in the central nervous system.
0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.
14 mg orally once daily, with or without food. Swallow whole; do not crush, chew, or dissolve.
None Documented
None Documented
Terminal elimination half-life is approximately 8–10 days due to slow dissociation from sphingosine 1-phosphate receptors; steady-state reached in 3–4 weeks.
Terminal elimination half-life is 48-56 hours, supporting once-daily dosing.
Primarily fecal (≈76% as metabolites) and renal (≈24% as metabolites and minor unchanged drug).
Renal: ~80% unchanged; biliary/fecal: ~20% as metabolites.
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator